Mental Health

Payton Nyquvest, CEO and founder of Numinus, said he believes psychedelic medicines will lead to a significant shift in the mental health treatment landscape in the next 3 to 5 years.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses the situations in which serotonin syndrome may be an area of concern when treating patients on psychiatric medication with psychedelic medicine.

Study results shows that patients who have been diagnosed with the disease may face many challenges, which can increase anxiety or depression.

The #PizzaIsNotWorking campaign originated because free pizza or other mundane incentives do not adequately address the unrealistic expectations in pharmacies, which lead to an emphasis on metrics rather than patient safety.

Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses what MAPS is, and how MAPS is engaged with the field of psychedelic medicine and its use in health care.

Misconceptions about the diagnosis of attention-deficit hyperactivity disorder reduce the credibility of health care providers and delay or prevent treatment for patients suffering from this condition.

The efficacy of Latuda in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.

Stacy Miller, senior content management consultant for Wolters Kluwer Health, discusses how mental health in the United States could be improved by stronger connections between prescribers and pharmacists.

Kelsey Ramsden, CEO of Mind Cure Health, said research into the use of MDMA-assisted therapy could have a huge impact on the treatment of female hypoactive sexual desire disorder.

Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses key points to consider regarding co-administration of MDMA, psilocybin, and ketamine with psychiatric medications, such as SSRI or SNRI antidepressants.

Senator Scott Wiener, discusses the California Senate Bill 519 he co-authored, which is the first and most expansive psychedelic decriminalization bill to go through a state legislature.

Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

There are several types of bipolar disorders, including mania or hypomania and depression.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

A panel of experts in the field of ketamine therapy discuss the role of the pharmacist in this field and the future of ketamine and assisted therapies based on current medical research.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

In a study, 92.5% of patients treated with the 6-month regimen of Invega and 95% of patients treated with the 3-month regimen were relapse-free at 12 months.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of psychedelic drugs like psilocybin.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients.

Cities were ranked on a 50 point scale, weighing factors including therapy session rate by state, total prescription charges by state, their grade for mandatory treatment laws by state, criminalization of mental illness by state, number of residents per 1 mental health provider by county, poor mental health days by county, and overall community wellbeing.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses the role of the pharmacist in ketamine therapy.

Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.

The amount of green space surrounding children’s homes may impact the development of ADHD.

Nicholas Mathews, co-founder of Stillwater Behavioral Health, discusses how pharmacists can respond to the identification of potentially problematic opioid prescription practices at sober-living facilities.

Although ADHD is generally treated through medication and/or behavioral treatments, in more than 25% of children, these treatments alone are insufficient.

Study suggests attention-deficit hyperactivity disorder medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.

Antidepressants may lower the risk of death and serious complications from diabetes for patients with both diabetes and depression, according to a study published in the Journal of Clinical Endocrinology & Metabolism.